share_log

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting With Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting With Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

捷豹健康將在美國臨床腫瘤學會(ASCO)年會上啓動癌症支持治療的商業版圖,屆時將展出經美國食品藥品管理局批准的Gelclair口腔粘膜炎產品展位
Accesswire ·  05/23 20:30

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force

根據全國綜合癌症網(NCCN)工作組的說法,口腔黏膜炎,也被稱爲"化療口腔炎",是腫瘤學中最顯著的不良事件。

Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea

公司第3階段試驗的最終結果即將出來。OnTarget 研究,一項針對受靶向治療的癌症患者的化療誘導腸道過度活躍(CIOB)預防性治療的關鍵第 3 期臨床試驗。用於預防癌症治療相關腹瀉的克浮地默(crofelemer)的第3階段試驗結果正在推出。

18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be diagnosed with cancer in 2024

美國有1800萬人患有癌症,並預計在2024年有超過200萬人將被診斷出癌症。

SAN FRANCISCO, CA / ACCESSWIRE / May 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it is initiating the company's commercial footprint in its core focus area of cancer supportive care at the May 31 - June 4 American Society of Clinical Oncology (ASCO) Annual Meeting with a Napo Pharmaceuticals (Napo) exhibit booth for Gelclair, the FDA-approved oral mucositis prescription product Jaguar in-licensed last month for the U.S. market. Napo is a Jaguar family company. Jaguar plans to begin the commercial launch in Q3 2024 for Gelclair.

加拿大虎健康公司(Jaguar Health, Inc.) (NASDAQ:JAGX)今天宣佈,將於5月31日至6月4日的美國臨床腫瘤學會(ASCO)年會上以納波(Napo)製備的Gelclair爲主題,展示公司癌症支持護理的商業足跡。該FDA批准的口腔黏膜炎處方藥是Jaguar上個月爲美國市場授權的新產品。Napo是虎家族公司。Jaguar計劃於2024年第三季度開始Gelclair的商業發行。虎健康公司計劃於2024年第三季度開始Gelclair的商業推出。

"Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a protective gel with a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis. Unlike other products for oral mucositis, it is not a numbing agent and does not sting the mouth," said Lisa Conte, Jaguar's president and CEO.

虎健康公司的總裁兼首席執行官麗莎·孔特(Lisa Conte)表示:"口腔黏膜炎是最常見、最痛苦、最能破壞癌症治療相關副作用之一。Gelclair是一種保護性凝膠,具有機械作用,可粘附於口腔黏膜表面,緩解口腔疾病的各種病因,包括口腔黏膜炎/口腔炎。與其他口腔黏膜炎產品不同,它不是麻痹劑,不會刺激口腔。"

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network (NCCN) task force.1 Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy. Of the latter, 19% may end up being hospitalized, experiencing a delay in antineoplastic treatment for high-grade mucositis management, resulting in a reduction of the quality of life, a worse prognosis, and an increase in patient management costs.2

根據全國綜合癌症網(NCCN)工作組的說法,口腔黏膜炎,也被稱爲"化療口腔炎",是腫瘤學中最顯著的不良事件。1接受化療的所有患者中,多達40%的人會出現口腔黏膜炎,對於接受化療和放療治療的頭頸癌患者,這個百分比上升到約90%。其中的19%可能需要住院,經歷治療高級別黏膜炎而延遲化療,導致生活質量降低、預後惡化和患者管理成本上升。2

Oral mucositis can negatively affect diet, nutrition, oral hygiene, as well as quality of life.3 Its adverse physical, social and psychological impacts on patients are manifest and include the need for total parenteral nutrition, higher risk of systemic infections, increased use of antifungals and opioid analgesics, increased hospitalizations with longer hospital stays, social isolation and depression due to the inability to talk and eat, subsequent dose reductions, treatment interruptions and discontinuations, and as a corollary to dose reductions and treatment interruptions/discontinuations, diminished anti-tumor responses and shorter survival.1

口腔黏膜炎會對飲食、營養、口腔衛生以及生活質量產生負面影響。3它對患者的身體、社交和心理有不良影響,包括需全胃腸外營養支持、患系統性感染的風險增加、抗真菌和阿片類藥物的大量使用增加、住院率增加並伴有更長的住院時間、由於無法言語和進食而導致社交隔離和抑鬱症、後續劑量減少、治療中斷和停止以及由於劑量減少和治療中斷/停止而導致抗腫瘤反應減弱和生存期縮短。1

"A key attribute in the management of head and neck cancer patients with Gelclair is, in my experience, to delay the onset which may decrease the severity of oral mucositis, allowing the patients to continue meeting their nutritional needs without having to go on a feeding tube, supporting their ability to withstand their 6 weeks of radiation therapy without having to go to lower doses or treatment interruptions, and to avoid the need for heavy prescription meds for oral mucositis-related pain," said Maged Ghaly, MD, a radiation oncologist at Northwell Health Cancer Institute, Monter Cancer Center.

北威爾健康腫瘤研究所(Monter Cancer Center)的放射腫瘤科醫生Maged Ghaly表示:"在我對使用Gelclair治療頭頸癌的患者的經驗中,關鍵特徵是延遲口腔黏膜炎的發生,這可以減輕口腔黏膜炎的嚴重程度,使患者在不使用餵養管的情況下繼續滿足其營養需要,支持他們在不降低劑量或中斷治療的情況下耐受6周的放療,並避免使用處方藥控制因口腔黏膜炎引起的疼痛。"

The economic consequences are far from trivial, with the incremental cost of oral mucositis exceeding $17,000 for patients with head and neck cancer.4

口腔黏膜炎的增量成本遠非微不足道,對於頭頸癌患者,口腔黏膜炎的成本超過17000美元。4

Gelclair is a clinically proven, convenient, and easy to use gel that provides rapid and long-lasting pain relief and improves the ability of oral mucositis patients to eat, drink, swallow, speak and sleep. Gelclair also reduces the need to use parenteral feeding or opiate analgesics.

Gelclair是一種經臨床證明的方便易用的凝膠,可快速和持久地緩解疼痛,並提高口腔黏膜炎患者進食、飲水、吞嚥、說話和睡眠能力。Gelclair還減少了使用腸道外營養或阿片類鎮痛藥的需要。

"We look forward to driving awareness among oncologists at the ASCO Annual Meeting about Gelclair and Jaguar's expanding focus on cancer supportive care," said Conte. "The depth of our commitment to people living with a cancer diagnosis is further exemplified by the 5-year commitment we've made to clinically study prophylaxis of cancer therapy-related diarrhea with our phase 3 OnTarget trial - specifically focusing on the more than 24 targeted cancer agents that have an incidence of greater than 50% diarrhea. Top line results from this pivotal study are imminent."

"我們期待在聚焦於癌症支持護理的ASCO年度會議上向腫瘤學家傳遞有關Gelclair以及Jaguar擴大其業務範圍的信息。"孔德表示。"我們對於致力於讓癌症患者獲得治療的承諾的深度得到了進一步的證明,這也由我們爲想在我們的OnTarget第三階段試驗中對預防癌症治療相關腹瀉進行臨床研究做出的5年承諾所證明,特別是針對24種目標癌症藥物進行研究,其中超過50%的癌症患者存在發生率的問題。這個重要研究的最終結果即將出來。"

About the Pivotal Phase 3 OnTarget Trial

關於OnTarget關鍵的第三階段試驗 OnTarget是一項長達24周(兩個12周的階段)的臨床試驗,其主要終點基於患者報告的結果,旨在應對減輕癌症治療相關腹瀉帶來的繁重負擔和未滿足的需求,這也是虎公司稱之爲化療誘發過度活躍腸綜合徵(CIOB)的指示-其中包括慢性和/或間歇性的令人難以忍受的腹瀉(鬆軟和/或水狀的大便)、緊急、腸道失禁、腹痛和不適。"

OnTarget is a first-of-its-kind, 24-week (two 12-week stages) clinical trial with a primary endpoint based on patient-reported outcomes that address the highly neglected and unmet burden of cancer therapy-related diarrhea, an indication Jaguar also refers to as preventive treatment of chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic and/or episodic debilitating diarrhea (loose and/or watery stools), urgency, bowel incontinence and abdominal pain and discomfort.

腹瀉是靶向治療的常見副作用,需要新的治療方法。依靠酪氨酸激酶抑制劑(TKIs)的患者中多達95%的人會出現腹瀉,具體取決於所使用的TKI。OnTarget試驗旨在測試該公司的植物性處方藥克浮地默(與安慰劑相比)在啓動24種不同的靶向治療(這些治療至少在50%的患者中與腹瀉相關)時是否能預防(或顯著減輕)腹瀉和其他CIOB症狀。根據美國癌症學會的數據,預計在2024年,超過200萬人將在美國被診斷出癌症。

Diarrhea is a common side effect of targeted therapies and new treatments are needed. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.5 The OnTarget study is testing whether the company's plant-based prescription drug crofelemer (versus placebo) can prevent (or substantially reduce) diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies (that are associated with diarrhea in at least 50% of patients) is initiated. More than 2 million people are expected to be diagnosed with cancer in 2024 in the U.S., according to the American Cancer Society.6 Cancer patients with diarrhea have been shown to be 40% more likely to discontinue their targeted therapy.7

依靠酪氨酸激酶抑制劑(TKIs)的患者中,多達95%的人會出現腹瀉,具體取決於所使用的TKI。5OnTarget試驗正在測試該公司的植物性處方藥克浮地默(與安慰劑相比)在啓動24種不同的靶向治療(這些治療至少在50%的患者中與腹瀉相關)時是否能預防(或顯著減輕)腹瀉和其他CIOB症狀。根據美國癌症學會的數據,預計在2024年,超過200萬人將在美國被診斷出癌症。6 癌症患者出現腹瀉的可能性要高出40%。7

About ASCO

關於ASCO

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer's full continuum. Learn more at .

美國臨床腫瘤學會成立於1964年,致力於知識征服癌症的原則。與臨床腫瘤學協會一起,ASCO代表近50000名腫瘤專業人士,爲關心癌症患者的人們提供護理。通過研究、教育和推廣高質量、公平的患者護理,ASCO致力於征服癌症,創造一個癌症被預防或治癒的世界,每個倖存者都很健康。Conquer Cancer,ASCO基金會通過資助癌症的全範圍的開創性研究和教育來支持ASCO。了解更多:。) 今天天氣不錯 今天天氣不錯

About Gelclair

關於Gelclair GELCLAIR有機械作用,適用於通過附着於口腔黏膜表面來緩解口腔潰瘍的各種病因,包括口腔黏膜炎/口炎(可能由化療或放療引起),口部手術引起的刺激,由於牙套或不合適的假牙引起的創傷性潰瘍,或疾病。也適用於瀰漫性口瘡。如果知道或懷疑對其任何成分過敏,請勿使用GELCLAIR。在臨床試驗中沒有報告任何不良影響,儘管後市場報告包括口腔灼燒感的偶發投訴。如果意外吞下GELCLAIR,不會預期出現任何不良影響。如果7天內沒有改善,應諮詢醫生。您被鼓勵向FDA報告處方醫療產品的負面副作用。訪問,致電1-855-273-0468,或填寫此鏈接上的表格。

INDICATIONS

適應症

GELCLAIR has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.

GELCLAIR適用於通過附着於口腔黏膜表面來緩解口腔潰瘍的各種病因,包括口腔黏膜炎/口炎(可能由化療或放療引起),口部手術引起的刺激,由於牙套或不合適的假牙引起的創傷性潰瘍,或疾病。也適用於瀰漫性口瘡。

IMPORTANT SAFETY INFORMATION

重要安全信息

Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.

如果已知或懷疑對其任何成分過敏,請勿使用GELCLAIR。

No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.

在臨床試驗中沒有報告任何不良影響,儘管後市場報告包括口腔灼燒感的偶發投訴。

If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.

如果意外吞下GELCLAIR,不會預期出現任何不良影響。

If no improvement is seen within 7 days, a physician should be consulted.

如果7天內沒有改善,應諮詢醫生。

You are encouraged to report negative side effects of prescription medical products to the FDA.

您被鼓勵向FDA報告處方醫療產品的負面副作用。

Visit , call 1-855-273-0468 or fill-in the form at this link.

訪問,致電1-855-273-0468,或填寫此鏈接上的表格。

Please see full Prescribing Information at:

請查看完整處方信息:

About the Jaguar Health Family of Companies

關於Jaguar Health公司家族

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

Jaguar Health,Inc(Jaguar)是一家商業階段的藥品公司,專注於研發新型從雨林地區的植物中可持續獲取的專有處方藥,以治療人類和動物的胃腸不適,特別是與腸道過度活躍相關的症狀,包括慢性令人殘疾的腹瀉、緊急情況、腸失禁和痙攣性疼痛。Jaguar旗下公司Napo Pharmaceuticals則專注於開發和銷售多種併發疾病狀態下治療基本支持和管理疏忽的胃腸症狀的人類處方藥。Napo Pharmaceuticals的crofelemer藥物候選產品是OnTarget研究的主題,這是一項關鍵的3期臨床試驗,旨在預防癌症患者在靶向治療期間出現化療誘導的過度胃腸活躍(CIOB)。Jaguar旗下公司Napo Therapeutics是一家於2021年在意大利米蘭成立的公司,專注於擴大歐洲地區,特別是孤兒或罕見疾病的crofelemer使用。Jaguar Animal Health是Jaguar的商標名稱。由Jaguar和Filament Health Corp成立的合資企業Magdalena Biosciences,從Jaguar的Entheogen Therapeutics Initiative(ETI)中發展而來,專注於開發從植物中獲取的新型處方藥,用於解決精神健康方面的問題。

For more information about:

更多信息:

Jaguar Health, visit

請訪問jaguar health。

Napo Pharmaceuticals, visit

請訪問Napo Pharmaceuticals。

Napo Therapeutics, visit napotherapeutics.com

請訪問napotherapeutics.com。

Magdalena Biosciences, visit magdalenabiosciences.com

請訪問magdalenabiosciences.com。

Visit Jaguar on LinkedIn:

在LinkedIn上訪問Jaguar:

Visit Jaguar on X:

訪問X上的Jaguar:

Visit Jaguar on Instagram:

在Instagram上訪問Jaguar:

Forward-Looking Statements

前瞻性聲明

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Napo will exhibit at the 2024 ASCO Annual Meeting, and Jaguar's expectation that the top line results from the OnTarget trial are imminent. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

本新聞稿中的某些聲明構成“前瞻性聲明”,包括Napo將在2024年ASCO年會上展出以及Jaguar期望OnTarget試驗的前線結果即將公佈的聲明。在某些情況下,您可以通過類似表達“可能”、“將”、“應該”、“期望”、“計劃”、“瞄準”、“預期”、“可能”、“計劃”、“瞄準”、“項目”、“考慮”、“相信”、“估計”、“預測”、“潛在”的術語來辨認前瞻性聲明,或其它類似的表述。本新聞稿中的前瞻性聲明僅表示預測。Jaguar主要基於其對未來事件的當前預期和預測,對這些前瞻性聲明進行了大部分基礎。這些前瞻性聲明僅於本發佈日期有效,並且受到許多風險、不確定性和假設的約束,其中一些無法預測或量化,另一些超出Jaguar的控制範圍。除適用法律要求外,Jaguar不打算公開更新或修訂此處所述的任何前瞻性聲明,無論是由於任何新信息、未來事件、改變的情況或其他因素。

1 Oronsky B, et al. Transl Oncol. 2018;11(3):771-778.

1Oronsky B,等人。Transl Oncol. 2018;11(3):771-778。

2 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. doi: 10.1186/s13046-020-01715-7. PMID: 33028357; PMCID: PMC7542970.

2Pulito C,Cristaudo A,Porta C,Zapperi S,Blandino G,Morrone A,Strano S。口腔黏膜炎:癌症治療的隱藏面。 J Exp Clin Cancer Res。2020年10月7日; 39(1):210。doi:10.1186 / s13046-020-01715-7。 PMID:33028357; PMCID:PMC7542970。

3 Jensen SB, Peterson DE. J Oral Pathol Med. 2014;43(2):81-90.

3Jensen SB,Peterson DE。J Oral Pathol Med。2014年; 43(2):81-90。

4 Nonzee NJ, et al. Cancer. 2008;113(6):1446-1452.

4Nonzee NJ等人。癌症。2008;113(6):1446-1452。

5 Moschen AR, Sammy Y, Marjenberg Z, Heptinstall AB, Pooley N, Marczewska AM. The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients. Curr Oncol Rep. 2022;24(7):861-874. doi:10.1007/s11912-022-01267-3

5Moschen AR,Sammy Y,Marjenberg Z,Heptinstall AB,Pooley N,Marczewska AM。癌症患者腹瀉和便秘的被低估和被忽視的負擔。Curr Oncol Rep。2022;24(7):861-874。doi:10.1007/s11912-022-01267-3

6

6

7 Pablo C. Okhuysen, M.D., The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence

7Pablo C. Okhuysen醫學博士,癌症相關腹瀉對癌症治療模式的影響:現實世界證據

Contact:

聯繫方式:

hello@jaguar.health
Jaguar-JAGX

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

資料來源:Jaguar Health, Inc。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論